Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

Background Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients benefit from them, and tools that could be used in...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurélien Marabelle, Laurence Albiges, Angelo Paci, Cécile Dalban, David Combarel, Sophie Broutin, Christophe Maritaz, Louis Blondel
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010059.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items